22-JAN-16

Husains

MARKET WRAP

The market has ended lower once again. The Sensex ended below 24000 for first

time since May 2014. The 30-share index was down 99.83 points or 0.4 percent at

23962.21 and the Nifty slipped 32.50 points or 0.4 percent at 7276.80. About 1289

shares advanced, 1301 shares declined and 184 shares were unchanged.

Axis Bank, Tata Steel, Wipro, SBI and Infosys were top gainers while Tata Motors, Dr

Reddy's Labs, Maruti, Coal India and ONGC were losers in the Sensex.

BROAD MARKET INDICES

INDEX P. CLOSE OPEN HIGH LOW CLOSE %CHANGE

NIFTY 50 7,309.30 7,376.65 7,398.70 7,250.00 7,276.80 -0.44

NIFTY NEXT 50 17,938.05 18,124.20 18,224.90 17,673.85 17,715.55 -1.24

NIFTY100 LIQ15 2,726.45 2,756.25 2,776.80 2,706.40 2,735.35 0.33

NIFTY MIDCAP 50 2,928.90 2,961.40 2,995.65 2,904.25 2,944.95 0.55

Contact No. +91-903-977-7700 www.moneyclassicresearch.com

ASIAN INDEXES

INDEX OPEN HIGH LOW CLOSE %CHANGE

NIKKEI 225 16,466.86 16,734.58 16,017.26 16,017.26 -2.49

HANG SENG 19,079.13 19,238.27 18,534.30 18,542.15 -1.86

TAIWAN 7,713.17 7,748.37 7,664.01 7,664.01 -0.46

SSE 2,934.39 2,998.79 2,880.08 2,880.80 -3.33

INDIAN MAJOR SECTORAL INDICES

INDEX P. CLOSE OPEN HIGH LOW CURRENT %CHANGE

NIFTY BANK 14,935.50 15,132.20 15,364.60 14,918.15 15,101.20 1.11

NIFTY FIN SERVICE 6,279.85 6,356.20 6,416.25 6,260.20 6,317.60 0.60

NIFTY PHARMA 11,133.65 11,241.00 11,243.95 10,825.50 10,876.60 -2.31

NIFTY IT 10,910.50 10,957.95 10,994.90 10,893.35 10,934.30 0.22

Contact No. +91-903-977-7700 www.moneyclassicresearch.com

STOCK UPDATE

Glenmark Pharma Gets USFDA Nod For Two Generic Drugs

Glenmark Pharma today said it has received final approval from the USFDA to manufacture and market Potassium Chloride extended release capsules and oral contraceptive Norethindrone Acetate and Ethinyl Estradiol tablets in the American market. Quoting IMS data, Glenmark Pharma said the approved product has an estimated market size of USD 74.1 million for the 12 months ended November 2015.The Company has also received approval for Norethindrone Acetate and Ethinyl Estradiol tablets. Glenmark Pharma's current portfolio consists of 62 ANDAs pending approvals from the US FDA and 106 products authorized for distribution in the US.

Contact No. +91-903-977-7700 www.moneyclassicresearch.com

Natco Pharma Signs Agreement for Manufacturing, Sale of

Hepatitis C Drug

Natco Pharma has signed a non-exclusive licensing agreement with the Medicines

Patent. Pool (MPP) and Bristol-Myers Squibb to manufacture and sell generic

versions of Daclatasvir, used for the treatment of chronic hepatitis C. Compared to

other treatment options, this combination not only increases the cure rate, but is

also regarded as a valuable treatment option in some of the difficult-to-treat HCV

patient subsets.

"This agreement allows Natco to expand access to these chronic hepatitis C

medicines in 112 developing countries. Under the licence, Natco can set its own

price for the generic products it produces," it said. Shares of Natco Pharma were

trading 4.06 per cent up at Rs 527.50 apiece on BSE.

Contact No. +91-903-977-7700 www.moneyclassicresearch.com